Patents by Inventor Michael Emmons

Michael Emmons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11928163
    Abstract: A technique is provided for creating digital memories for a particular person. A data store stores personal data derived from signals gathered from a plurality of sensors that monitor the particular person. Memories creation processing circuitry, responsive to detection of a given event associated with the particular person, performs an augmentation process to generate an augmented given event identifying multiple items of data associated with the given event, including personal data associated with the given event obtained from the data store. The memories creation processing circuitry analyses the multiple items of data identified by the augmented given event in order to generate a given digital memory for the given event. A memories data store stores digital memories generated by the memories creation processing circuitry for the particular person, and memories analysis circuitry determines and maintains associations between the digital memories in the memories data store.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: March 12, 2024
    Assignee: Arm Limited
    Inventors: Remy Pottier, Minsheng Lu, Arthur Michael Goldberg, Christopher Daniel Emmons
  • Publication number: 20140080762
    Abstract: The subject invention pertains to compositions and methods for treatment of malignancies and inhibiting the growth of cancer cells, such as multiple myeloma and other hematologic malignancies, using HYD1 peptides. Other aspects of the invention are directed to methods for selection of agents useful in the treatment of malignancies and inhibiting the growth of cancer cells. Further aspects of the invention include methods for determining whether a cancer is sensitive or resistant to treatment with HYD1 peptides based on the presence of certain biomarkers, such as ?4 integrin and CD44 expression.
    Type: Application
    Filed: March 21, 2012
    Publication date: March 20, 2014
    Applicants: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Lori Anne Hazlehurst, William S. Dalton, Michael Emmons, Anthony W. Gebhard